Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Dec;40(12):1261-1263.
doi: 10.1007/s40273-022-01200-3. Epub 2022 Nov 11.

Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia"

Bhaskar Rege  1 , James McGrory  2 , Sabina Gasper  2 , David McDonnell  3
Affiliations
Comment

Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia"

Bhaskar Rege et al. Pharmacoeconomics. 2022 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Bhaskar Rege, James McGrory, and Sabina Gasper are employees of Alkermes, Inc., and may be shareholders. David McDonnell is an employee of Alkermes Pharma Ireland Ltd. and may be a shareholder.

Comment in

Comment on

References

    1. Piena MA, Houwing N, Kraan CW, Wang X, Waters H, Duffy RA, et al. An integrated pharmacokinetic–pharmacodynamic-pharmacoeconomic modeling method to evaluate treatments for adults with schizophrenia. Pharmacoeconomics. 2022;40(1):121–131. doi: 10.1007/s40273-021-01077-8. - DOI - PMC - PubMed
    1. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Tardy M, Komossa K, et al. Maintenance treatment with antipsychotic drugs for schizophrenia. Cochrane Database Syst Rev. 2020;8:CD008016. doi: 10.1002/14651858.CD008016.pub3. - DOI - PMC - PubMed
    1. Ceraso A, Lin JJ, Schneider-Thoma J, Siafis S, Heres S, Kissling W, et al. Maintenance treatment with antipsychotic drugs in schizophrenia: a Cochrane systematic review and meta-analysis. Schizophr Bull. 2022;48(4):738–740. doi: 10.1093/schbul/sbac041. - DOI - PMC - PubMed
    1. Wang X, Raoufinia A, Bihorel S, Passarell J, Mallikaarjun S, Phillips L. Population pharmacokinetic modeling and exposure-response analysis for aripiprazole once monthly in subjects with schizophrenia. Clin Pharm Drug Dev. 2022;11(2):150–164. doi: 10.1002/cpdd.1022. - DOI - PMC - PubMed
    1. Citrome L. Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil. Expert Rev Clin Pharmacol. 2016;9(2):169–186. doi: 10.1586/17512433.2016.1121809. - DOI - PubMed